Actelion Pharmaceuticals ^Company

Actelion Pharmaceuticals is a Swiss biopharmaceutical company that focuses on the discovery, development, and commercialization of low molecular weight drugs for various medical needs. Its principal products include Tracleer, an orally available dual endothelin receptor antagonist, approved as a therapy for pulmonary arterial hypertension (PAH) and Zavesca, an oral medication indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. The company also offers Ventavis, an inhaled synthetic analogue of prostacyclin that produces potent pulmonary vasodilation and inhibits platelet aggregation. Actelion markets Tracleer in several countries and has an exclusive worldwide alliance with Merck & Co, Inc. to discover, develop, and market new classes of renin inhibitors for patients suffering from cardio-renal diseases.